Oppenheimer Starts Neurocrine Bio. (NBIX) at Perform

Oppenheimer initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Perform rating and a price target of $55.00.

Analyst Jay Olson commented, "We initiate coverage of Neurocrine Biosciences (NBIX) with a Perform rating and a $55 price target. NBIX develops drugs that modulate the CNS and endocrine systems, thus targeting movement disorders and women’s health. We appreciate the company’s impressive pipeline progress in two distinct therapeutic areas but remain agnostic given the stock's current price, which is near our price target."

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $51.01 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• JPMorgan Downgrades Beijing Easpring Material Technology Co Ltd. (300073:CH) to Underweight
• BOK Financial (BOKF) PT Raised to $100 at Keefe, Bruyette & Woods